Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-248 + Daratumumab vs DPd in Relapsed or Refractory Multiple Myeloma
NCT07742215Phase 3Recruiting
- Sponsor
- BIOCAD
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 2
01
Overview
A Phase 3 trial of BCD-248 in multiple myeloma (MM), sponsored by BIOCAD. Started Jun 2026; status: recruiting.
02
Drugs
BCD-248
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07742215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742215.